Immune-Related Adverse Event Guideline: Hepatoxicity

Hepatic transaminases (ALT/AST) and bilirubin must be evaluated before each dose of immunotherapy, as early laboratory changes may indicate emerging immune-related hepatitis. Elevations in LFTs may develop in the absence of clinical symptoms.

This guidance should be used in context of baseline LFTs and presence of known liver metastases. No dose adjustment is required but data is limited for use of these drugs in moderate/severe hepatic impairment and patients should be closely monitored for elevation in LFTs from baseline.



**** IMPORTANT **Subsequent management of patients with hepatitis that is either not improving, or worsening should always be discussed with a gastroenterologist and the patient's oncologist**

Subsequent management guideline– Hepatitis

Outpatient management



Inpatient Management